In Brief: Fresenius USA
This article was originally published in The Gray Sheet
Executive SummaryFresenius USA: Company selects Salomon Brothers Inc. to aid in the assessment and negotiation of economic terms on which FUSA would participate in combining Fresenius AG, FUSA and W.R. Grace's National Medical Care unit into Fresenius Medical Care. Under terms of the definitive agreement, announced Feb. 4, Fresenius AG would purchase 55% of NMC for $2.3 mil. in cash. FUSA is approximately 70% owned by Germany-based Fresenius AG...
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.